Group Inc. (Palo Alto, Calif.) Stem cell therapy Tumor stem cell-specific dendritic cell therapy Hepatocellular carcinoma Achieved 50% enrollment of the total projected enrollment for the Phase I trial 5/23/13 Cytrx Corp. (Los Angeles) Aldoxorubicin A conjugate of doxorubicin Metastatic solid tumors Phase Ib data showed a distribution half-life of 20 hours to 24 hours following infusion, which is significantly longer than doxorubicin's initial half-life of five minutes 5/23/13 DCPrime BV
Due to this considerable growth, the Nasdaq OMX Group Inc., of New York, said it is modifying the methodology used to arrive at a valuation for the Nasdaq Biotechnology Index (NBI
By BioWorld Staff | BioWorld Today | Tuesday, June 11, 2013
Effective on that date, its common stock now trades for quotation on the OTCQB, an electronic quotation service operated by OTC Markets Group Inc...Regen BioPharma, of San Diego, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc., submitted responses to the FDA's comments regarding its investigational new drug application for HemaXellerate, for immune suppressant-resistant aplastic anemia
Cellular Biomedicine Group Inc., of Palo Alto, Calif., achieved 50 percent enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of tumor stem cell-specific dendritic cell therapy for hepatocellular carcinoma
Cellular Biomedicine Group Inc., of Palo Alto, Calif., achieved 50 percent enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of human adipose-derived mesenchymal progenitor cells therapy for knee osteoarthritis
The Nasdaq OMX Group Inc., of New York, reported the semi-annual re-ranking of the Nasdaq Biotechnology Index, which will become effective prior to the market's open on May 20
Amgen Inc.'s $1 billion buyout in 2011 of BioVex Group Inc., which brought aboard the melanoma therapy then known as OncoVex, may be paying off, but analysts are waiting for overall survival (OS) Phase III data before they start jumping up and down about the compound, now called talimogene laherparepvec, or T-VEC
By Randy Osborne | BioWorld Today | Thursday, March 21, 2013
Details Date Champions Oncology Inc. (Hackensack, N.J.) Private placement of common stock 18.6S $9.3 Champions Oncology raised $9.3M at 50 cents per share with Battery Ventures IX LP, PAR Investment Partners LP, Harris and Harris Group Inc
Champions Oncology Inc., of Hackensack, N.J., raised $9.3 million at 50 cents per share in a private placement of 18.6 million shares of common stock with lead investors Battery Ventures IX L.P., PAR Investment Partners L.P., Harris and Harris Group Inc
By Catherine Shaffer | BioWorld Today | Thursday, January 31, 2013
Group Inc. (Palo Alto, Calif.) Stem cell therapy Tumor stem cell-specific dendritic cell therapy Hepatocellular carcinoma Achieved 50% enrollment of the total projected enrollment for the Phase I trial 5/23/13 Cytrx Corp. (Los Angeles) Aldoxorubicin A conjugate of doxorubicin Metastatic solid tumors Phase Ib data showed a distribution half-life of 20 hours to 24 hours following infusion, which is significantly longer than doxorubicin's initial half-life of five minutes 5/23/13 DCPrime BV